ESR1 and breast cancer: Supportively, several well-characterized pharmacologic inhibitors of DNA methylation such as 5-aza-20-deoxycytidine (5-aza-dc) and histone deacetylation such as trichostatin A (TSA) were demonstrated to reactivate ERα expression in ERα− breast cancer cells, respectively [11–13].